/MLYS
MLYS Stock - Mineralys Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$36.83-0.46%
$0.17 (-0.46%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.2%upside
Target: $52.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MLYS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$36.46 – $37.20
TARGET (TP)$52.00
STOP LOSS$33.88
RISK/REWARD1:5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.40
52W High$47.65
52W Low$8.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-192,403,000 | $-84,657,000 | $-31,479,000 | $-18,725,000 | $-2,943,000 |
| Net Income | $-177,810,000 | $-71,898,000 | $-29,799,000 | $-19,408,000 | $-3,426,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.66 | $-1.99 | $-5.77 | $-3.89 | $-0.74 |
Company Overview
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
88%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$32
Average Target
↓ 12.4% Downside
Now
$15
Low
$32
Average
$45
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 11th 2025 | Jefferies | Initiation | Hold | $15 |
| July 10th 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| April 2nd 2024 | Goldman | Initiation | Buy | $30 |
| March 7th 2023 | Evercore ISI | Initiation | Outperform | - |
| March 7th 2023 | BofA Securities | Initiation | Buy | $39 |
| March 7th 2023 | Guggenheim | Initiation | Buy | $32 |
| March 7th 2023 | Wells Fargo | Initiation | Overweight | $27 |
| March 7th 2023 | Stifel | Initiation | Buy | $45 |
| March 7th 2023 | Credit Suisse | Initiation | Outperform | $40 |
Earnings History & Surprises
MLYSBeat Rate
67%
Last 12 quarters
Avg Surprise
-4.4%
EPS vs Estimate
Beats / Misses
8/4
Last 12 quarters
Latest EPS
$-0.52
Q4 2025
EPS Surprise History
Q1 24
+28.2%
$-0.61vs$-0.85
Q2 24
-2.9%
$-0.70vs$-0.68
Q3 24
-13.7%
$-0.83vs$-0.73
Q4 24
-36.1%
$-1.13vs$-0.83
Q1 25
+2.0%
$-0.98vs$-1.00
Q2 25
+22.5%
$-0.79vs$-1.02
Q3 25
+15.4%
$-0.66vs$-0.78
Q4 25
+21.2%
$-0.52vs$-0.66
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.57 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.66 | $-0.52 | +21.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.78 | $-0.66 | +15.4% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-1.02 | $-0.79 | +22.5% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-1.00 | $-0.98 | +2.0% | ✓ BEAT |
Q4 2024 | Nov 11, 2024 | $-0.83 | $-1.13 | -36.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.73 | $-0.83 | -13.7% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.68 | $-0.70 | -2.9% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.85 | $-0.61 | +28.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.72 | $-0.57 | +20.8% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.83 | $-0.31 | +62.7% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.71 | $-0.51 | +28.2% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $1.72 | $-1.74 | -201.2% | ✗ MISS |
Q1 2023 | Feb 10, 2023 | — | $-1288.84 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.35 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.41 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.18 | — | — |
Latest News
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
📈 PositiveBenzinga•Dec 19, 2025, 02:45 PM•Also:
Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Research Of The Year Roundup"
📈 PositiveBenzinga•Dec 12, 2025, 04:02 PM
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56
📈 PositiveBenzinga•Nov 12, 2025, 11:50 AM
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55
📈 PositiveBenzinga•Nov 11, 2025, 02:27 PM
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:08 PM
Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases
📈 PositiveBenzinga•Nov 10, 2025, 09:42 AM
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
📈 PositiveBenzinga•Oct 30, 2025, 11:54 AM
Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
➖ NeutralBenzinga•Oct 21, 2025, 12:08 PM
Mineralys Therapeutics Completes Enrollment In Phase 2 EXPLORE-OSA Trial Of Lorundrostat In Participants With Moderate-To-Severe OSA And Hypertension
📈 PositiveBenzinga•Sep 30, 2025, 12:09 PM
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Sep 11, 2025, 12:36 PM
Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
📈 PositiveBenzinga•Sep 9, 2025, 05:39 PM
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 11:03 AM
Mineralys Therapeutics Presents Subgroup Data From Phase 3 Launch-HTN Trial At AHA 2025, Highlighting Lorundrostat's Efficacy In High-Risk Hypertension Populations
📈 PositiveBenzinga•Sep 5, 2025, 01:03 PM
Jefferies Maintains Hold on Mineralys Therapeutics, Raises Price Target to $26
📈 PositiveBenzinga•Sep 3, 2025, 11:18 AM
Reported Earlier, Mineralys Therapeutics Prices Upsized $250M Public Offering Of 9.8M Shares Of Common Stock At $25.50 Per Share
📉 NegativeBenzinga•Sep 3, 2025, 06:46 AM
Mineralys Therapeutics Suspends Prospectus Supplement For ATM Equity Offering
📉 NegativeBenzinga•Sep 2, 2025, 09:08 PM
Mineralys Therapeutics Commences $175M Public Offering With $26.25M Over-Allotment Option
📈 PositiveBenzinga•Sep 2, 2025, 08:04 PM
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $43
📈 PositiveBenzinga•Aug 28, 2025, 03:49 PM
Frequently Asked Questions about MLYS
What is MLYS's current stock price?
Mineralys Therapeutics, Inc. (MLYS) is currently trading at $36.83 per share. The stock has moved -0.46% today.
What is the analyst price target for MLYS?
The average analyst price target for MLYS is $52.00, based on 1 analyst.
What sector is Mineralys Therapeutics, Inc. in?
Mineralys Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MLYS's market cap?
Mineralys Therapeutics, Inc. has a market capitalization of $2.44 billion, making it a mid-cap company.
Does MLYS pay dividends?
No, Mineralys Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
AGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
APLS
Apellis Pharmaceuticals, Inc.
$24.65
Mkt Cap: $3.1B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to MLYS for comparison